Please use this identifier to cite or link to this item:
Title: mTOR Expression in Liver Transplant Candidates with Hepatocellular Carcinoma: Impact on Histological Features and Tumour Recurrence.
Authors: Guerrero, Marta
Ferrín, Gustavo
Rodríguez-Perálvarez, Manuel
González-Rubio, Sandra
Sánchez-Frías, Marina
Amado, Víctor
Pozo, Juan C
Poyato, Antonio
Ciria, Rubén
Ayllón, María D
Barrera, Pilar
Montero, José L
de la Mata, Manuel
Keywords: hepatocellular carcinoma;immunosuppression;liver transplantation;mTOR
metadata.dc.subject.mesh: Carcinoma, Hepatocellular
Kaplan-Meier Estimate
Liver Neoplasms
Liver Transplantation
Middle Aged
Multivariate Analysis
Neoplasm Recurrence, Local
Proportional Hazards Models
ROC Curve
Signal Transduction
TOR Serine-Threonine Kinases
Issue Date: 15-Jan-2019
Abstract: (1) Background: The mammalian target of rapamycin (mTOR) pathway activation is critical for hepatocellular carcinoma (HCC) progression. We aimed to evaluate the mTOR tissue expression in liver transplant (LT) patients and to analyse its influence on post-LT outcomes. (2) Methods: Prospective study including a cohort of HCC patients who underwent LT (2012⁻2015). MTOR pathway expression was evaluated in the explanted liver by using the "PathScan Intracellular Signalling Array Kit" (Cell Signalling). Kaplan-Meier and Cox regression analyses were performed to evaluate post-LT HCC recurrence. (3) Results: Forty-nine patients were included (average age 56.4 ± 6, 14.3% females). Phospho-mTOR (Ser2448) was over-expressed in peritumoral tissue as compared with tumoral tissue (ΔSignal 22.2%; p
metadata.dc.identifier.doi: 10.3390/ijms20020336
Appears in Collections:Producción 2020

Files in This Item:
File SizeFormat 
PMC6359509.pdf3,07 MBAdobe PDFView/Open

This item is protected by original copyright

This item is licensed under a Creative Commons License Creative Commons